share_log

Gemini Therapeutics (NASDAQ:GMTX) Shares Down 6.4%

Gemini Therapeutics (NASDAQ:GMTX) Shares Down 6.4%

双子疗法（纳斯达克股票代码：GMTX）股价下跌6.4％
Financial News Live ·  2022/12/17 09:11

Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Rating)'s stock price dropped 6.4% during mid-day trading on Thursday . The company traded as low as $1.52 and last traded at $1.55. Approximately 51,834 shares traded hands during trading, a decline of 72% from the average daily volume of 182,922 shares. The stock had previously closed at $1.65.

双子座治疗公司(Gemini Treateutics，Inc.)股价周四午盘下跌6.4%，最低报1.52美元，尾盘报1.55美元。全天约有51,834股易手，较182,922股的日均成交量下跌72%。该股此前收盘报1.65美元。

Gemini Therapeutics Trading Up 0.6 %

双子座治疗公司股价上涨0.6%

The company has a market cap of $67.38 million, a PE ratio of -1.56 and a beta of -0.12. The business has a fifty day moving average of $1.71 and a 200-day moving average of $1.61.

该公司市值为6738万美元，市盈率为-1.56，贝塔系数为-0.12。该业务的50日移动均线切入位在1.71美元，200日移动均线切入位在1.61美元。

Get
到达
Gemini Therapeutics
双子座治疗公司
alerts:
警报：

Insider Activity at Gemini Therapeutics

双子座治疗公司的内部活动

In related news, major shareholder Braden Michael Leonard sold 22,500 shares of the business's stock in a transaction dated Wednesday, October 26th. The stock was sold at an average price of $2.09, for a total transaction of $47,025.00. Following the transaction, the insider now owns 247,500 shares in the company, valued at approximately $517,275. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.90% of the stock is owned by company insiders.

在相关新闻中，大股东布拉登·迈克尔·伦纳德在10月26日星期三的交易中出售了22,500股该公司的股票。该股以2.09美元的平均价格出售，总成交金额为47,025.00美元。交易完成后，这位内部人士现在拥有该公司247,500股，价值约517,275美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过美国证券交易委员会网站。12.90%的股份由公司内部人士持有。

Institutional Inflows and Outflows

机构资金流入和流出

Hedge funds have recently bought and sold shares of the business. MYDA Advisors LLC grew its holdings in shares of Gemini Therapeutics by 215.0% during the 3rd quarter. MYDA Advisors LLC now owns 63,000 shares of the company's stock worth $103,000 after acquiring an additional 43,000 shares during the period. Nantahala Capital Management LLC purchased a new position in shares of Gemini Therapeutics during the 3rd quarter worth approximately $423,000. ExodusPoint Capital Management LP purchased a new position in shares of Gemini Therapeutics during the 3rd quarter worth approximately $85,000. Assenagon Asset Management S.A. grew its holdings in shares of Gemini Therapeutics by 423.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 82,171 shares of the company's stock worth $135,000 after acquiring an additional 66,467 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Gemini Therapeutics by 80.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 36,635 shares of the company's stock worth $62,000 after acquiring an additional 16,297 shares during the period. Hedge funds and other institutional investors own 83.40% of the company's stock.
对冲基金最近买卖了该公司的股票。MYDA Advisors LLC在第三季度增持了双子座治疗公司的股票215.0%。MYDA Advisors LLC在此期间增持了43,000股，现在拥有63,000股该公司股票，价值103,000美元。南塔哈拉资本管理公司在第三季度购买了价值约42.3万美元的双子座治疗公司的新股票。ExodusPoint资本管理公司在第三季度购买了价值约8.5万美元的双子座治疗公司的新股票。Assenagon Asset Management S.A.在第三季度增持双子座治疗公司股票423.2%。Assenagon Asset Management S.A.在此期间增持了66,467股，目前持有82,171股该公司股票，价值135,000美元。最后，高盛公司在第二季度增持了双子座治疗公司的股票80.1%。高盛股份有限公司在此期间增持了16,297股，目前持有36,635股该公司股票，价值62,000美元。对冲基金和其他机构投资者持有该公司83.40%的股票。

About Gemini Therapeutics

关于双子座治疗公司

(Get Rating)

(获取评级)

Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.

Gemini治疗公司是一家临床阶段精准药物公司，致力于开发各种治疗化合物，用于治疗遗传定义的年龄相关性黄斑变性(AMD)。它的主要候选药物是GEM103，一种重组形式的人类补体因子H蛋白，用于治疗干性AMD患者。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on Gemini Therapeutics (GMTX)
  • MarketBeat: Week in Review 12/12 – 12/16
  • Which Two Bluechip Tech Companies Have Raised Their Guidance?
  • Should You Worry About Elon Musk Selling His Tesla Shares?
  • Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
  • This is no Time to Buy Lennar but the Time is Coming
  • 免费获取StockNews.com关于双子座治疗(GMTX)的研究报告
  • MarketBeat：回顾一周12/12-12/16
  • 哪两家蓝筹科技公司提高了他们的指引？
  • 你应该担心埃隆·马斯克出售他持有的特斯拉股票吗？
  • 拖拉机库存能否突破杯柄收购点？
  • 现在不是购买Lennar的时候，但时机即将到来

Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接受《双子座治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对双子座治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发